Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 10/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 10/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 10/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 10/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.68 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.68 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.68 |
| ▸ | CFTR | P13569 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381258 | 0.96 | PDE4A (0.92) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7458212 | 0.94 | PDE4A (0.89) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| Iodide SCHEMBL28973314 | 0.94 | PDE4A (0.89) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL8656750 | 0.93 | PDE4A (0.87) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7460178 | 0.91 | PDE4A (1.00) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3186630 | 0.91 | PDE4A (0.94) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL11361392 | 0.90 | PDE4A (0.91) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL21381240 | 0.88 | ADORA2B (0.94) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL21381259 | 0.88 | PDE4A (1.00) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3842077 | 0.88 | PDE4A (1.00) | PDE4AADORA2APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0956855-B1 | Immunosuppressive effects of 8 substituted xanthine derivatives | LEUVEN K U RES & DEV (BE) | 2003-03-12 | — | — | EP | claimed |
| EP-0956855-A1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. Leuven Research & Development (BE) | 1999-11-17 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3042934-B1 | COLORED COMPOSITION, CURED FILM, COLOR FILTER, COLOR-FILTER MANUFACTURING METHOD, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, POLYMER, AND XANTHENE DYE | FUJIFILM CORP (JP) | 2022-11-09 | — | — | EP | disclosed |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | PDE4A 1873/4885ADORA2A 3171/4885PDE4B 1806/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | PDE4A 1873/4885ADORA2A 3171/4885PDE4B 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.